Trials / Completed
CompletedNCT02044328
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation: a Prospective, Exploratory Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Betta Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage IIA-IIIA adenocarcinoma patients with EGFR mutation. The primary endpoint is disease-free survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Icotinib | Icotinib is administered 125 mg three times per day. |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2018-01-01
- Completion
- 2021-10-01
- First posted
- 2014-01-23
- Last updated
- 2022-02-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02044328. Inclusion in this directory is not an endorsement.